

HR 4117

Competitive DRUGS Act of 2017

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Oct 25, 2017

Current Status: Referred to the Subcommittee on Digital Commerce and Consumer Protection.

Latest Action: Referred to the Subcommittee on Digital Commerce and Consumer Protection. (Oct 27, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/4117>

Sponsor

Name: Rep. Doggett, Lloyd [D-TX-35]

Party: Democratic • **State:** TX • **Chamber:** House

Cosponsors (37 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Castor, Kathy [D-FL-14]	D · FL		Oct 25, 2017
Rep. Chu, Judy [D-CA-27]	D · CA		Oct 25, 2017
Rep. Cicilline, David N. [D-RI-1]	D · RI		Oct 25, 2017
Rep. Cohen, Steve [D-TN-9]	D · TN		Oct 25, 2017
Rep. Conyers, John, Jr. [D-MI-13]	D · MI		Oct 25, 2017
Rep. Cummings, Elijah E. [D-MD-7]	D · MD		Oct 25, 2017
Rep. DeLauro, Rosa L. [D-CT-3]	D · CT		Oct 25, 2017
Rep. Ellison, Keith [D-MN-5]	D · MN		Oct 25, 2017
Rep. Grijalva, Raúl M. [D-AZ-3]	D · AZ		Oct 25, 2017
Rep. Kaptur, Marcy [D-OH-9]	D · OH		Oct 25, 2017
Rep. Khanna, Ro [D-CA-17]	D · CA		Oct 25, 2017
Rep. Langevin, James R. [D-RI-2]	D · RI		Oct 25, 2017
Rep. Nadler, Jerrold [D-NY-10]	D · NY		Oct 25, 2017
Rep. Napolitano, Grace F. [D-CA-32]	D · CA		Oct 25, 2017
Rep. O'Rourke, Beto [D-TX-16]	D · TX		Oct 25, 2017
Rep. Pingree, Chellie [D-ME-1]	D · ME		Oct 25, 2017
Rep. Pocan, Mark [D-WI-2]	D · WI		Oct 25, 2017
Rep. Raskin, Jamie [D-MD-8]	D · MD		Oct 25, 2017
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Oct 25, 2017
Rep. Velazquez, Nydia M. [D-NY-7]	D · NY		Oct 25, 2017
Rep. Jayapal, Pramila [D-WA-7]	D · WA		Nov 28, 2017
Rep. Welch, Peter [D-VT-At Large]	D · VT		Nov 28, 2017
Rep. Blumenauer, Earl [D-OR-3]	D · OR		Jan 18, 2018
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Apr 11, 2018
Rep. Cartwright, Matt [D-PA-17]	D · PA		Jun 15, 2018
Rep. Larson, John B. [D-CT-1]	D · CT		Jul 11, 2018
Rep. Bass, Karen [D-CA-37]	D · CA		Jul 19, 2018
Rep. Cleaver, Emanuel [D-MO-5]	D · MO		Jul 19, 2018
Rep. DeSaulnier, Mark [D-CA-11]	D · CA		Jul 19, 2018
Rep. Gonzalez, Vicente [D-TX-15]	D · TX		Jul 19, 2018
Rep. Green, Al [D-TX-9]	D · TX		Jul 19, 2018
Rep. Gutierrez, Luis V. [D-IL-4]	D · IL		Jul 19, 2018
Rep. Moore, Gwen [D-WI-4]	D · WI		Jul 19, 2018
Rep. Shea-Porter, Carol [D-NH-1]	D · NH		Jul 19, 2018
Rep. Thompson, Bennie G. [D-MS-2]	D · MS		Jul 19, 2018
Rep. Waters, Maxine [D-CA-43]	D · CA		Sep 4, 2018
Rep. Gallego, Ruben [D-AZ-7]	D · AZ		Nov 30, 2018

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 27, 2017
Judiciary Committee	House	Referred To	Oct 25, 2017
Ways and Means Committee	House	Referred To	Oct 25, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Oct 25, 2017)

Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017

This bill establishes a series of requirements and prohibitions regarding certain patent infringement agreements between brand name and generic drug manufacturers in which the generic drug manufacturer agrees to delay the availability of applicable generic drugs. Among other things, the bill specifies that such agreements constitute an unfair method of competition and are subject to specified civil penalties.

Actions Timeline

- **Oct 27, 2017:** Referred to the Subcommittee on Digital Commerce and Consumer Protection.
- **Oct 25, 2017:** Introduced in House
- **Oct 25, 2017:** Referred to the Committee on Ways and Means, and in addition to the Committees on the Judiciary, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.